Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw unusually-high trading volume on Thursday . Approximately 1,542,775 shares changed hands during trading, an increase of 690% from the previous session’s volume of 195,207 shares.The stock last traded at $27.00 and had previously closed at $26.35.

Wall Street Analyst Weigh In

DNTH has been the topic of several analyst reports. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 price target on the stock. Raymond James lifted their price target on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Wedbush dropped their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday. Finally, Oppenheimer boosted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Stock Performance

The company’s fifty day moving average price is $27.70 and its 200 day moving average price is $26.64. The firm has a market capitalization of $808.89 million, a price-to-earnings ratio of -10.54 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DNTH. Vanguard Group Inc. boosted its stake in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after purchasing an additional 384,182 shares during the period. StemPoint Capital LP acquired a new position in Dianthus Therapeutics during the 1st quarter valued at about $1,304,000. Bain Capital Life Sciences Investors LLC acquired a new stake in shares of Dianthus Therapeutics in the 1st quarter worth approximately $89,761,000. Janus Henderson Group PLC acquired a new stake in shares of Dianthus Therapeutics in the 1st quarter worth approximately $11,251,000. Finally, RA Capital Management L.P. acquired a new stake in shares of Dianthus Therapeutics in the 1st quarter worth approximately $69,990,000. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.